Summit Therapeu ADR (SMMT)

Mar 24, 2025, 2:17 PM EDT - 9 days ago

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

Mar 21, 2025, 4:15 PM EDT - 11 days ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2025, 4:24 PM EDT - 15 days ago

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Feb 24, 2025, 8:13 PM EST - 5 weeks ago

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

PFE

Feb 24, 2025, 3:33 PM EST - 5 weeks ago

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program

Feb 24, 2025, 12:15 PM EST - 5 weeks ago

Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 10:53 AM EST - 5 weeks ago

Pfizer: What The Summit Therapeutics Deal Brings

PFE

Feb 24, 2025, 6:05 AM EST - 5 weeks ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Feb 24, 2025, 6:00 AM EST - 5 weeks ago

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

PFE

Feb 18, 2025, 9:00 AM EST - 6 weeks ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Jan 18, 2025, 9:33 AM EST - 2 months ago

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

Jan 13, 2025, 6:10 PM EST - 2 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 7, 2025, 7:00 AM EST - 3 months ago

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 11:46 PM EST - 3 months ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD JANX LUNR

Dec 2, 2024, 2:10 PM EST - 4 months ago

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Nov 26, 2024, 4:15 PM EST - 4 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2024, 2:14 PM EST - 5 months ago

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo

Oct 30, 2024, 1:27 PM EDT - 5 months ago

Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 5 months ago

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Oct 23, 2024, 4:15 PM EDT - 5 months ago

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

Oct 4, 2024, 10:35 AM EDT - 6 months ago

Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track

Oct 3, 2024, 4:15 PM EDT - 6 months ago

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Sep 19, 2024, 2:33 PM EDT - 6 months ago

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

MRK

Sep 16, 2024, 6:30 AM EDT - 7 months ago

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

Sep 13, 2024, 6:52 PM EDT - 7 months ago

Trade It or Fade It: The week's big biotech moves

BNTX MRK

Sep 12, 2024, 6:30 AM EDT - 7 months ago

Summit Therapeutics Raises $235 Million

Sep 11, 2024, 6:28 PM EDT - 7 months ago

Summit Therapeutics Co-CEOs on what's next for lung cancer drug

Sep 9, 2024, 12:45 PM EDT - 7 months ago

Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC Subpopulation

Sep 9, 2024, 10:17 AM EDT - 7 months ago

BA Reaches Union Deal, COST Price Target Hike, MRK Down as SMMT Rallies

BA COST MRK

Sep 9, 2024, 9:57 AM EDT - 7 months ago

Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today

Sep 9, 2024, 9:14 AM EDT - 7 months ago

Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial

MRK

Sep 9, 2024, 8:02 AM EDT - 7 months ago

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half

MRK

Sep 8, 2024, 11:45 AM EDT - 7 months ago

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China

Aug 12, 2024, 7:00 AM EDT - 8 months ago

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

Aug 11, 2024, 7:30 PM EDT - 8 months ago

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

Aug 9, 2024, 8:55 PM EDT - 8 months ago

Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 8 months ago

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

BCYC BSY MASS MLI NJR OFIX QBTS

Aug 6, 2024, 7:00 AM EDT - 8 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

Aug 3, 2024, 5:16 AM EDT - 8 months ago

Summit Therapeutics May Have Further Upside From Here

Jul 29, 2024, 4:15 PM EDT - 8 months ago

Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024

Jul 25, 2024, 8:00 AM EDT - 8 months ago

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

Jun 27, 2024, 4:15 PM EDT - 9 months ago

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

Jun 3, 2024, 9:42 AM EDT - 10 months ago

Summit Therapeutics stock rallies as institutional buyer loads up on shares

Jun 3, 2024, 5:30 AM EDT - 10 months ago

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

Jun 1, 2024, 8:00 AM EDT - 10 months ago

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

May 31, 2024, 7:00 PM EDT - 10 months ago

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

May 30, 2024, 4:29 PM EDT - 10 months ago

Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster

MRK

May 30, 2024, 3:39 PM EDT - 10 months ago

Summit Therapeutics cancer therapy succeeds in late-stage China study

May 30, 2024, 2:29 PM EDT - 10 months ago

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China

May 8, 2024, 1:30 PM EDT - 11 months ago

Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide